New combo therapy aims to boost immune attack on Hard-to-Treat cancers
NCT ID NCT06130826
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This early-phase study tests a new drug called M5A-IL2 immunocytokine together with precise radiation (SBRT) in people with advanced colorectal or breast cancer that has spread. The drug helps the immune system recognize and attack cancer cells. The goal is to find the safest dose and see if the combination shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Phone-Based navigation could boost breast cancer detection in kenya
- Can delivering cancer drug directly to the liver shrink tumors?
- A simple blood draw could spot colorectal cancer early
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- Can a Cancer-Fighting virus shrink tumors when chemo fails?
- One dose may not fit all: blood tests could tailor cancer drug dosing